188775-25-9

Basic information

• Product Name: Carbonic acid, 4-nitrophenyl tetrahydro-3-furanyl ester
• CAS NO: 188775-25-9
• Molecular Formula: C11H11NO6
• Molecular Weight: 253.211
• Mol File: 188775-25-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Carbonic acid, 4-nitrophenyl tetrahydro-3-furanyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, 4-nitrophenyl tetrahydro-3-furanyl ester(188775-25-9)
• EPA Substance Registry System: Carbonic acid, 4-nitrophenyl tetrahydro-3-furanyl ester(188775-25-9)

Safety Data

• Hazardous Substances Data: 188775-25-9(Hazardous Substances Data)

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 124391-75-9 3-tetrahydrofuranmethanol 

Downstream Products

• 1607592-56-2 tetrahydrofuran-3-yl [(trans-4-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}cyclohexyl)methyl]carbamate 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC COMPOUNDS

The present invention relates to substituted heterocyclic compounds of Formula I or XI: or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine II4 receptor inhibitors useful in the treatment of histamine II4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.